 |
Use Drug Link Subheadings in EMBASE®?
TOPIC: Biomedical information professionals often get questions about drug administration and dosage. These questions have two aspects.
- How can I find citations about the route of administration and/or drug dosage, including the relationship between dosage and its effects over time?
- How can I find articles about a specific route of administration of a specific drug?
EMBASE® (File 72) indexing makes it easy to get timely and accurate answers. You can quickly find abstracts where the route of administration and dosage issues are significant parts of the article, and you can link particular routes of drug administration to a specific drug and make it a major descriptor term. For details and search aids on using EMTREE click here. For a list of EMTREE routes of administration subheading links click here.
In this application you will search for articles about drug administration and dosage of Lipitor® and link directly to records about oral administration of this drug. You will use EXPAND and SELECT to do this.
COMMAND SUMMARY
BEGIN 72
EXPAND (LIPITOR)
EXPAND ATORVASTATIN
SELECT E7 OR E13
SELECT S1/MAJ,HUMAN,ENG
TYPE S2/8/1-3
TYPE S2/7/1
EXPAND ATORVASTATIN
SELECT E21/MAJ
TYPE S3/8/1-3
TYPE S3/7/2
HOW TO...
1. BEGIN File 72 to search EMBASE.
2. EXPAND the drug brand name. Use parentheses to get directly to the preferred term. “U” means Use this term.
|
?b 72
File 72:EMBASE 1993-2007/Mar 22
(c) 2007 Elsevier B.V.
Set Items Description
--- ----- -----------
?e (lipitor)
Ref Items Type RT Index-term
R1 769 1 *LIPITOR
R2 8043 U 18 ATORVASTATIN
Enter P or PAGE for more |
3. EXPAND the preferred drug term to see the list of allowable subheadings.
4. SELECT the desired E reference numbers.
Note: You can also SELECT the drug term linked directly to the desired subheading using the Link operator (L).
S ATORVASTATIN (L) (AD OR DO)
5. SELECT Set 1 (S1) and restrict retrieval to major focus about human subjects in English language.
|
?e atorvastatin
Ref Items RT Index-term
E1 2 ATORVASTAFIN
E2 4 ATORVASTAIN
E3 8043 18 *ATORVASTATIN
E4 1346 ATORVASTATIN --ADVERSE DRUG REACTION --AE
E5 1 ATORVASTATIN --BUCCAL DRUG ADMINISTRATION --BD
E6 2437 ATORVASTATIN --CLINICAL TRIAL --CT
E7 26 ATORVASTATIN --DRUG ADMINISTRATION --AD
E8 137 ATORVASTATIN --DRUG ANALYSIS --AN
E9 1088 ATORVASTATIN --DRUG COMBINATION --CB
E10 1637 ATORVASTATIN --DRUG COMPARISON --CM
E11 124 ATORVASTATIN --DRUG CONCENTRATION --CR
E12 82 ATORVASTATIN --DRUG DEVELOPMENT --DV
E13 1662 ATORVASTATIN --DRUG DOSE --DO
E14 708 ATORVASTATIN --DRUG INTERACTION --IT
E15 5573 ATORVASTATIN --DRUG THERAPY --DT
....
?s e7 or e13
26 ATORVASTATIN --DRUG ADMINISTRATION --AD
1662 ATORVASTATIN --DRUG DOSE --DO
S1 1668 'ATORVASTATIN --DRUG ADMINISTRATION --AD' OR
'ATORVASTATIN --DRUG DOSE --DO'
?s s1/maj,human,eng
S2 608 S1/MAJ,HUMAN,ENG |
6. TYPE a few records in Format 8 to view title, descriptors and publication year.
The asterisk (*) in front of the descriptor indicates that the term is a major focus of the article.
Note: Partial records shown. |
?t s2/8/1-2
2/8/1
DIALOG(R)File 72: EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14321524 EMBASE No: 2007080061
Effect of individualizing starting doses of a statin
according to baseline LDL-cholesterol levels on achieving
cholesterol targets: The Achieve Cholesterol Targets Fast
with Atorvastatin Stratified Titration (ACTFAST) study
Publication Date: 2007
DRUG DESCRIPTORS:
* atorvastatin--clinical trial--ct; *atorvastatin--drug
dose--do; * atorvastatin--drug therapy--dt; *low density
lipoprotein cholesterol --endogenous compound--ec; *statine
derivative--clinical trial--ct; * statine derivative--drug
dose--do; *statine derivative--drug therapy--dt
acetylsalicylic acid; angiotensin 2 receptor antagonist;
anticoagulant agent--oral drug administration--po;
antithrombocytic agent; dipeptidyl carboxypeptidase
inhibitor
2/8/2
DIALOG(R)File 72: EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14312934 EMBASE No: 2007092359
Adherence to evidence-based statin guidelines reduces the
risk of hospitalizations for acute myocardial infarction
by 40%: A cohort study
Publication Date: 2007
DRUG DESCRIPTORS:
* atorvastatin--drug comparison--cm; *atorvastatin--drug
dose--do; * atorvastatin--drug therapy--dt;
*cerivastatin--drug comparison--cm; * cerivastatin--drug
dose--do; *cerivastatin--drug therapy--dt; *
fluindostatin--drug comparison--cm; *fluindostatin--drug
dose--do; * fluindostatin--drug therapy--dt;
*pravastatin--drug comparison--cm; * pravastatin--drug
dose--do; *pravastatin--drug therapy--dt;
*rosuvastatin --drug comparison--cm; .... |
7. TYPE a record in Format 7 to see the Bibliographic Citation and Abstract.
Note: Partial record shown. |
?t s9/7/1
9/7/1
DIALOG(R)File 72: EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14321524 EMBASE No: 2007080061
Effect of individualizing starting doses of a statin
according to baseline LDL-cholesterol levels on achieving
cholesterol targets: The Achieve Cholesterol Targets Fast
with Atorvastatin Stratified Titration (ACTFAST) study
Martineau P.; Gaw A.; de Teresa E.; Farsang C.;
Gensini G.F.; Leiter L.A.; Langer A.
A. Langer, St. Michael's Hospital, University of
Toronto, Toronto, Ont. Canada
Author Email: Langera@chrc.net
Atherosclerosis ( ATHEROSCLEROSIS ) ( Ireland )
2007 , 191/1 (135-146)
CODEN: ATHSB ISSN: 0021-9150
Publisher Item Identifier: S0021915006001274
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 48
Aims: To investigate whether selecting the starting
dose of atorvastatin according to baseline and target
(<2.6 mmol/L) LDL-cholesterol (LDL-C) values would allow
high-risk subjects to achieve target LDL-C concentration
within 12 weeks, with the initial dose or a single
uptitration. Methods and results: Twelve-week, prospective,
open-label trial that enrolled 2117 high-risk subjects
(statin-free [SF] or statin-treated [ST]). Subjects with
LDL-C >2.6 mmol/L (100 mg/dL) but <=5.7 mmol/L (220 mg/dL)
were assigned a starting dose of atorvastatin (10, 20, 40
or 80 mg/day) based on LDL-C and status of statin use at
baseline, with a single uptitration at 6 weeks, if
required. There was no washout for ST subjects. At study
end, 80% of SF (82%, 82%, 83% and 72% with 10, 20, 40 and
80 mg, respectively) and 59% of ST (60%, 61% and 51% with
20, 40 and 80 mg, respectively) subjects reached LDL-C
target. In the ST group, an additional 21-41% reduction
in LDL-C was observed over the statin used at baseline.
Atorvastatin was well tolerated. Conclusion: This study
confirms that individualizing the starting dose of
atorvastatin according to baseline and .... (c) 2006
Elsevier Ireland Ltd. All rights reserved. |
8. EXPAND the preferred drug term. In this section you want to find citations about a specific route of administration of the drug.
9. SELECT the desired E reference number and restrict retrieval to Major Descriptor /MAJ.
|
?e atorvastatin
Ref Items RT Index-term
E1 2 ATORVASTAFIN
E2 4 ATORVASTAIN
E3 8043 18 *ATORVASTATIN
E4 1346 ATORVASTATIN --ADVERSE DRUG REACTION --AE
E5 1 ATORVASTATIN --BUCCAL DRUG ADMINISTRATION --BD
E6 2437 ATORVASTATIN --CLINICAL TRIAL --CT
E7 26 ATORVASTATIN --DRUG ADMINISTRATION --AD
E8 137 ATORVASTATIN --DRUG ANALYSIS --AN
E9 1088 ATORVASTATIN --DRUG COMBINATION --CB
E10 1637 ATORVASTATIN --DRUG COMPARISON --CM
E11 124 ATORVASTATIN --DRUG CONCENTRATION --CR
E12 82 ATORVASTATIN --DRUG DEVELOPMENT --DV
E13 1662 ATORVASTATIN --DRUG DOSE --DO
E14 708 ATORVASTATIN --DRUG INTERACTION --IT
E15 5573 ATORVASTATIN --DRUG THERAPY --DT
E16 47 ATORVASTATIN --DRUG TOXICITY --TO
E17 1 ATORVASTATIN --ENDOGENOUS COMPOUND --EC
E18 3 ATORVASTATIN --INTRAGASTRIC DRUG ADMINISTRATIO
E19 11 ATORVASTATIN --INTRAPERITONEAL DRUG ADMINISTRA
E20 3 ATORVASTATIN --INTRAVENOUS DRUG ADMINISTRATION
E21 281 ATORVASTATIN --ORAL DRUG ADMINISTRATION --PO
E22 115 ATORVASTATIN --PHARMACEUTICS --PR
?s e21/maj
S3 170 'ATORVASTATIN --ORAL DRUG ADMINISTRATION
--PO'/MAJ |
10. TYPE a few records in Format 8.
Note: Partial records shown.
To select the appropriate record number, look at the numbers above each record, e.g. 3/8/2.
|
?t s3/8/1-3
3/8/1
DIALOG(R)File 72: EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14307443 EMBASE No: 2007069116
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
Atorvastatin mediated effects depend on the activation
status of target cells in PLP-EAE
Publication Date: 2006
Manufacturer Names: American Peptide/United States;
Pfizer/Germany; Sortis/Germany
Molecular Sequence Number: ; GENBANK, AI385532; GENBANK,
AK003671; GENBANK, B1499717; GENBANK, BB353211; GENBANK,
BE686578; GENBANK, D00208; GENBANK, NM 007707; GENBANK,
NM 008339; GENBANK, NM 008969; GENBANK, NM 008987;
GENBANK, NM 010288; GENBANK, NM 020008; GENBANK, X16834
DRUG DESCRIPTORS:
* atorvastatin--drug therapy--dt; *atorvastatin--oral drug
administration--po ; *atorvastatin--pharmacology--pd;
*hydroxymethylglutaryl coenzyme A reductase inhibitor--drug
therapy--dt; *hydroxymethylglutaryl coenzyme A reductase
inhibitor--pharmacology--pd; *proteolipid protein--
subcutaneous drug administration--sc CD86 antigen--
endogenous compound--ec; Freund adjuvant; cyclooxygenase
1 --endogenous compound--ec; intercellular adhesion molecule
1--endogenous compound--ec
. . .
Drug Terms (Uncontrolled): heat shock protein 105--endogenous
compound--ec
CAS Registry Number: 9007-81-2 (Freund adjuvant); 134523-00-5,
134523-03-8 (atorvastatin); 126547-89-5 (intercellular
adhesion molecule 1)
3/8/2
DIALOG(R)File 72: EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14305105 EMBASE No: 2007052812
Aspirin augments 15-epi-lipoxin ASUB4 production by
lipopolysaccharide, but blocks the pioglitazone and
atorvastatin induction of 15-epi-lipoxin ASUB4 in the
rat heart
Publication Date: 2007
Manufacturer Names: Pfizer/United States; Takeda/United
States
DRUG DESCRIPTORS:
* acetylsalicylic acid--drug interaction--it;
*acetylsalicylic acid--oral drug administration--po;
*acetylsalicylic acid--pharmacology--pd; *
atorvastatin--drug interaction--it; *atorvastatin--oral
drug administration --po; *atorvastatin--pharmacology--pd;
*lipopolysaccharide; *lipoxin A --endogenous compound--ec;
*pioglitazone--drug interaction--it; * pioglitazone--oral
drug administration--po; *pioglitazone--pharmacology--pd
2,4 thiazolidinedione derivative--drug interaction--it;
6 oxoprostaglandin F1 alpha--endogenous compound--ec;
arachidonate 15 lipoxygenase--endogenous compound--ec; ....
. . .
Drug Terms (Uncontrolled): 15 epilipoxin A4--endogenous
compound--ec
CAS Registry Number: 493-53-8, 50-78-2, 53663-74-4,
53664-49-6, 63781-77-1 (acetylsalicylic acid );
82249-77-2 (arachidonate 15 lipoxygenase); 134523-00-5,
134523-03-8 ( atorvastatin); 4371-52-2, 52-89-1, 52-90-4
(cysteine); 89663-86-5, 94292-80-5 (lipoxin A); 105355-27-9,
111025-46-8 (pioglitazone); 745-62-0 ( prostaglandin F1
alpha); 42935-17-1 (prostaglandin H2); 56-45-1, 6898-95-9
(serine) |
11. TYPE a desired record(s) in Format 7, which provides the Bibliographic Citation and Abstract.
Note: A partial record is shown. |
?t 3/7/2
3/7/2
DIALOG(R)File 72: EMBASE
(c) 2007 Elsevier B.V. All rights reserved.
14305105 EMBASE No: 2007052812
Aspirin augments 15-epi-lipoxin ASUB4 production by
lipopolysaccharide, but blocks the pioglitazone and
atorvastatin induction of 15-epi-lipoxin ASUB4 in the
rat heart
Birnbaum Y.; Ye Y.; Lin Y.; Freeberg S.Y.; Huang M.-H.;
Perez-Polo J.R.; Uretsky B.F.
Y. Birnbaum, The Division of Cardiology, University of
Texas Medical Branch, 301 University Blvd, Galveston,
TX 77555-0553 United States
Author Email: yobirnba@utmb.edu
Prostaglandins and Other Lipid Mediators ( PROSTAGLANDINS
OTHER LIPID MEDIATORS ) ( United States ) 2007 ,
83/1-2 (89-98)
CODEN: POLMF ISSN: 1098-8823
Publisher Item Identifier: S1098882306001468
Document Type: Journal ; Article
Language: ENGLISH Summary Language: ENGLISH
Number Of References: 22
Aspirin (ASA) inhibits cycloxygenase-1 and modifies
cycloxygenase-2 (COX2) by acetylation at SerSUP530,
leading to a shift from production of PGHSUB2, the
precursor of prostaglandin, to 15-R-HETE which is
converted by 5-lipoxygenase to 15-epi-lipoxin ASUB4
(15-epi-LXA4), a potent anti-inflammatory mediator.
Both atorvastatin (ATV) and pioglitazone (PIO) increase
COX2 expression. ATV activates COX2 by S-nitrosylation
at CysSUP526 to produce 15-epi-LXA4 and
6-keto-PGFSUB1alpha (the stable metabolite of PGISUB2).
We assessed the effect of ASA on the myocardial
production of 15-epi-LXA4 and PGISUB2 after induction
by lipopolysaccharide (LPS) or PIO + ATV. Sprague-Dawley
rats were pretreated with: control; ASA 10 mg/kg; ASA
50 mg/kg; LPS alone; LPS + ASA 10 mg/kg; LPS + ASA 50
mg/kg; LPS + ASA 200 mg/kg; PIO (10 mg/kg/d) + ATV
(10 mg/kg/d); PIO + ATV + ASA 10 mg/kg; PIO + ATV +
ASA 50 mg/kg; PIO + ATV + ASA 50 mg/kg + 1400 W, a
specific iNOS inhibitor; or PIO + ATV + 1400 W. ASA
alone had no effect on myocardial 15-epi-LXA4. LPS
increased 15-epi-LXA4 and 6-keto-PGFSUB1alpha levels.
ASA (50 mg/kg and 200 mg/kg, but not 10 mg/kg) augmented
the LPS effect on 15-epi-LXA4 but attenuated the effect
on 6-keto-PGFSUB1alpha. PIO + ATV increased 15-epi-LXA4
and 6-keto-PGFSUB1alpha levels. ASA and 1400 W attenuated
the effects of PIO + …. |
RELATED HOW DO I...? SOLUTIONS
NEED HELP?
Contact the Dialog Knowledge Center
Within North America 1 800 3 DIALOG (334 2564)
Outside North America 0 800 33 DIALOG (33 34 2564)
Web Form www.dialog.com/contacts/webform
|
You are viewing the
Click below to view the
 |
